Cytopenias Are ‘Limited’ Following Ide-Cel in R/R Multiple Myeloma

Commentary
Video

The safety profile of idecabtagene vicleucel in relapsed/refractory multiple myeloma following the first 3 months of treatment appears to be comparable with standard therapies, says Rachid Baz, MD.

During the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition, Rachid Baz, MD, spoke with CancerNetwork® about how safety data from the phase 3 KarMMa-3 trial (NCT03651128) showed a low rate of cytopenias and infections with idecabtagene vicleucel (ide-cel; Abecma) as a therapy for patients with relapsed/refractory multiple myeloma.

According to Baz, the Myeloma Section head in the Department of Malignant Hematology at Moffitt Cancer Center and co-director of the Pentecost Family Myeloma Research Center, safety signals in the KarMMa-3 trial were expected based on results from a prior assessment of ide-cel in relapsed/refractory multiple myeloma in the phase 2 KarMMa-1 trial (NCT03361748). Additionally, cytopenias and infections generally occurred early during treatment, and the overall safety profile of ide-cel following the first 3 months of therapy appeared to be comparable with standard multiple myeloma treatment options.

Data from the KarMMa-3 trial highlighted that the rates of grade 3/4 cytopenias with ide-cel were 87.1% at fewer than 3 months, 24.1% at more than 3 and fewer than 6 months, and 14.7% at more than 6 months compared with standard regimens. Cytopenias in the ide-cel arm were typically managed with colony-stimulating factor (55.5%), red blood cell transfusions (48.0%), and platelet transfusions (32.0%).

Transcript:

The main implication is that there was not a signal [in KarMMa-3] that we did not anticipate from the KarMMa-1 study. Cytopenias are something hematologists are usually comfortable managing or something comfortable for us to deal with. I typically use growth factor support and transfusion support when needed. It is very rare that patients require things like a stem cell boost. That’s our experience with CAR T so far.

In that specific patient population, we saw that the reassuring part is that a lot of this [toxicity] was limited. We saw it mostly in the first 3 months of treatment.The same was true for infection. When you look at bacterial infection, they were more common in the first 3 months of treatment. Beyond the first 3 months, the rate was not very different than what you would see in a patient population receiving a [standard] myeloma therapy.

Reference

Baz R, Otero PR, Ailawadhi S, et al. Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): analysis of cytopenias and infections in pts from KarMMa-3. Blood. 2023;1429(suppl 1):4879. doi:10.1182/blood-2023-174477

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
OSZAR »